American Oncology Network (AONC)
OTHER OTC:AONC
Want to see AONC full AI Analyst Report?
Top Page
American Oncology Network
(OTC:AONC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$7.00
▼(-46.15% Downside)
Action:Reiterated
Date:01/22/26
The score is primarily weighed down by weak financial health—persistent losses, negative operating/free cash flow, and negative equity—despite strong revenue growth. Technicals also remain bearish with the stock below all major moving averages and a negative MACD, while valuation signals are limited because the negative P/E is driven by losses and there is no dividend support.
Positive Factors
Top-line Growth
Sustained multi-year revenue expansion indicates the platform is successfully scaling affiliated practices and ancillary services. Durable top-line growth supports network effects, bargaining power with payers and vendors, and provides a larger base to invest in operations and clinical programs over the medium term.
Negative Factors
Persistent losses
Ongoing unprofitability undermines internal funding for growth and clinical investments, forcing reliance on external financing. Over a multi-month horizon, persistent losses increase refinancing risk, constrain strategic flexibility, and can impede execution of expansion or integration initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Top-line Growth
Sustained multi-year revenue expansion indicates the platform is successfully scaling affiliated practices and ancillary services. Durable top-line growth supports network effects, bargaining power with payers and vendors, and provides a larger base to invest in operations and clinical programs over the medium term.
Read all positive factors
American Oncology Network (AONC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$441.58M
Dividend YieldN/A
Average Volume (3M)1.34K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1,914
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,129,753
10 Day Avg. Volume102
30 Day Avg. Volume1,341
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.70
Price to Sales (P/S)0.04
P/FCF Ratio-2.68
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda239.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
American Oncology Network Business Overview & Revenue Model
Company Description
American Oncology Network (AONC) is a leading provider of oncology services dedicated to improving cancer care across the United States. AONC partners with independent community oncologists to enhance the delivery of cancer treatment while maintai...
How the Company Makes Money
American Oncology Network generates revenue primarily through a combination of patient services, including the administration of chemotherapy and other cancer treatments, as well as clinical trials and research services. The company's revenue mode...
American Oncology Network Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
35
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.76B | 1.28B | 1.15B | 943.75M | 724.74M |
| Gross Profit | 117.85M | 82.80M | 95.45M | 77.96M | 66.11M |
| EBITDA | 1.81M | -39.35M | 23.09M | 7.85M | 25.94M |
| Net Income | -3.97M | -5.54M | 2.59M | -105.00K | 21.95M |
Balance Sheet | |||||
| Total Assets | 470.33M | 374.45M | 326.23M | 248.30M | 49.03K |
| Cash, Cash Equivalents and Short-Term Investments | 72.64M | 63.93M | 36.78M | 27.35M | 25.00K |
| Total Debt | 147.37M | 128.32M | 127.13M | 63.69M | 0.00 |
| Total Liabilities | 362.32M | 303.74M | 264.21M | 22.26M | 24.87K |
| Stockholders Equity | 18.77M | -161.73M | 62.02M | 312.62M | 24.17K |
Cash Flow | |||||
| Free Cash Flow | -25.90M | -30.40M | -13.98M | -34.66M | 25.02M |
| Operating Cash Flow | -4.94M | -18.12M | -6.78M | -26.34M | 37.24M |
| Investing Cash Flow | -2.41M | -35.40M | -13.99M | -333.50M | -14.67M |
| Financing Cash Flow | 41.66M | 55.13M | 15.35M | 335.53M | 16.26M |
American Oncology Network Technical Analysis
Positive
13.00
Price Trends
9.99
Positive
10.80
Positive
10.59
Positive
Market Momentum
0.38
Negative
64.81
Neutral
53.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AONC, the sentiment is Positive. The current price of 13 is above the 20-day moving average (MA) of 9.67, above the 50-day MA of 9.99, and above the 200-day MA of 10.59, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 64.81 is Neutral, neither overbought nor oversold. The STOCH value of 53.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AONC.
American Oncology Network Risk Analysis
American Oncology Network disclosed 54 risk factors in its most recent earnings report. American Oncology Network reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
American Oncology Network Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $421.94M | -17.34 | -27.10% | ― | -20.37% | -479.68% | |
56 Neutral | $1.34B | 1.10 | -146.01% | ― | -2.82% | -45.70% | |
54 Neutral | $446.92M | -313.53 | 326.77% | ― | 35.37% | 46.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $441.58M | -8.72 | ― | ― | ― | ― | |
41 Neutral | $390.34M | -0.16 | 5.89% | ― | -2.87% | ― |
* Healthcare Sector Average
AONC
American Oncology Network
12.00
5.64
88.68%
CYH
Community Health
2.80
-0.87
-23.71%
CCRN
Cross Country Healthcare
13.05
-0.47
-3.48%
TOI
Oncology Institute
4.59
1.58
52.49%
AGL
Agilon Health
86.39
30.89
55.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.